
|Articles|September 30, 2015
Pharmacist Provider Status Bill Update
A status report of the Pharmacy and Medically Underserved Areas Enhancement Act.
Advertisement
Pharmacy and Medically Underserved Areas Enhancement Act
HR.592 introduced by US Rep. Brett Guthrie and S.314 introduced by US Sen. Chuck Grassley:
- Formally recognizes pharmacists as health care providers under Medicare Part B
- Follows states’ scope of practice for all licensed pharmacists
- Serves patients in medically underserved areas (73 of Arkansas’s 75 counties count as “underserved”)
Hurdles to Passage
- Cost of implementing the bill has not yet been released by the Congressional Budget Office
- Poor understanding of “pharmacist services” and the ways pharmacists provide value
- Bill needs 230 cosponsors (22 sponsors away) from moving forward in the US House of Representatives
- There is a lot of room for more pharmacy advocates. Only 7500 of the nation's estimated 290,000 pharmacists have sent letters to Congress in support of the bill.
Future Hurdles
- Studies showing cost versus savings of pharmacists being formally recognized as providers
- Copays/medical coding issues
- Documentation practice standardization
- Billing issues
- Tracking pharmacist readiness
- Workflow issues
What Pharmacists Can Do Today
- Sign up for the Pharmacists Provide Care Coalition Newsletter
- Send a quick “Thank You” or “Please Support” email to your Representatives and Senators.
- Spread the word on social media and include patient-focused messaging
Key Takeaways
- More co-sponsors are needed to get the bill passed by Congress in its current session.
- The bill should be “scored” by the Congressional Budget Office in the coming weeks or months.
- The bill does not grant prescriptive authority unless it is already in a state’s scope of practice for pharmacists.
- The bill only pertains to pharmacists being recognized as providers under Medicare Part B.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
2
Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer
3
Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer
4
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
5